Oligonucleotide Inhibition for cardiac regeneration in Ischemia

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41HL134387-01A1
Agency Tracking Number: R41HL134387
Amount: $225,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NHLBI
Solicitation Number: PA16-303
Solicitation Year: 2016
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-04-01
Award End Date (Contract End Date): 2018-09-30
Small Business Information
8150 GILMAN CT, La Jolla, CA, 92037-2933
DUNS: 079805635
HUBZone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: N
Principal Investigator
 (858) 869-3564
Business Contact
Phone: (858) 869-3564
Email: bhawanjit.brar@gmail.com
Research Institution
 9500 Gilman Drive, Mail Code 0934
LA JOLLA, CA, 92093-0934
 Nonprofit college or university
PROJECT SUMMARY Ischemic heart disease IHD is the single largest cause of death worldwide A heart attack or myocardial infarction MI results from limitation of coronary blood flow to the heart causing ischemia and ultimately irreversible death of cardiomyocytes The size of a myocardial infarct correlates with the degree of deterioration of heart function compromise of contractile reserve and overtime the likelihood of mortality from heart failure HF Prompt restoration of arterial perfusion with thrombolytic and antiplatelet therapy during percutaneous coronary intervention has led to a decline in acute mortality from MI However the prevalence of HF among survivors has augmented because irreversible cardiomyocyte death results in a residual inducible ischemia and permanent scarring A major pathologic problem is the failure of human adult cardiomyocytes to regenerate themselves endogenously following a MI This is compounded by a lack of adjunctive treatments pharmacologic or cellular that can be administered in conjunction with reperfusion or after to stimulate regeneration of heart muscle Effective promotion of endogenous cardiomyocyte regeneration in the ischemic heart with concomitant reduction of scar size would potentially offer a powerful new treatment of MI and its adverse pathophysiologic consequences Inhibition of a specific combination of four MicroRNAs miR miR miR let a and let c is a critical regulator of cardiomyocyte dedifferentiation and heart regeneration in zebrafish The sequences and target proteins of these miRs are conserved in humans In vivo adeno associated virus AAV delivery of inhibitors of these miRs into the hearts of mice with left coronary artery ligation increases the expression of the beta subunit of farnesyl transferase and SWI SNF related matrix associated actin dependent regulator of chromatin subfamily a member Cardiac regeneration was confirmed by the expression of proliferation and cytokinesis markers labeled uridine incorporation into DNA together with scar tissue regression and heart functional improvement A disadvantage of viral delivery is the high prevalence of anti AAV antibodies in humans that could neutralize their effect As an alternative JAAN Biotherapeutics will investigate whether two synthetic specific potent and nuclease resistant nucleic acid miR inhibitors anti miRs to miR and let a c can reduce ischemic injury in an experimental murine model of ischemic reperfusion and constitute an innovative approach to regenerate human cardiomyocytes The research in Phase I will define whether the anti miRs proliferate normal heart muscle provide information on an effective dose and sustainability of effect and establish any proliferative or off target side effects in remote tissues Aim Aim will study whether the anti miRs administered after a min cardiac ischemic injury in mice either at the time of reperfusion or days after ischemia can reduce scar size increase cardiac function and regenerate cardiac muscle Aim will provide safety information and Aim is critical to confirm efficacy of the anti miRs in the murine ischemic heart These studies are pivotal for future preclinical and clinical study design PROJECT NARRATIVE The proposal s objective is to develop a therapy that can be given to patients shortly after a heart attack to improve their long term outcome and prevent heart failure the single largest cause of death in the world The academic partner has developed mouse models of ischemic heart disease and methods that provide precise three dimensional visualization and quantification of heart damage and function The small business partner is studying an innovative ribonucleic acid interference technology that regenerates damaged cardiac muscle by reactivating an evolutionary conserved process In partnership we intend to test whether two synthetic ribonucleic nucleic acid inhibitors regenerate heart muscle without side effects and can reduce the pathophysiology of cardiac ischemic injury in mice Information on the dose sustainability of effect and timing of administration to regenerate heart muscle will enable the design of future safety toxicology studies potentially allowing clinical development that may improve the long term outcome for patients with ischemic heart disease

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government